

Bovilis IBR marker Live

Authorised

- Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated

Product identification

Medicine name:

Bovilis IBR marker Live

BOVILIS IBR MARKER LIVE LYOPHILISAT ET SOLVANT POUR SUSPENSION POUR BOVINS

Active substance:

Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated

Target species:

Cattle

Route of administration:

Nasal use

Intramuscular use

Product details

Active substance and strength:

Bovine herpesvirus 1, strain GK/D gE gene-deleted, Inactivated

5.70 log₁₀ 50% tissue culture infectious dose / 2.00 millilitre(s)

Pharmaceutical form:

Lyophilisate for suspension for injection

Withdrawal period by route of administration:

Nasal use:

•

Cattle

- Milk. no withdrawal period zero days
- Meat and offal. no withdrawal period zero days

Intramuscular use:

•

Cattle

- Milk. no withdrawal period zero days
- Meat and offal. no withdrawal period zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AD01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

France

Available in:

France

Package description:

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (100 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (200 ml)

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (10 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (20 ml)

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (100 ml)

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (50 doses) and a cardboard box with 10 PET vials of solvent (100 ml)

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (5 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (10 ml)

Cardboard box with 10 glass vials (hydrolytic type I) of lyophilisate (25 doses) and a cardboard box with 10 glass vials (hydrolytic type II) of solvent (50 ml)

Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 glass vial (hydrolytic type II) of solvent (100 ml)

Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (50 doses) and 1 PET vial of solvent (100 ml)

Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (5 doses) and 1 glass vial (hydrolytic type II) of solvent (10 ml)

Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (25 doses) and 1 glass vial (hydrolytic type II) of solvent (50 ml)

Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (100 doses) and 1 glass vial (hydrolytic type II) of solvent (200 ml)

Cardboard box with 1 glass vial (hydrolytic type I) of lyophilisate (10 doses) and 1 glass vial (hydrolytic type II) of solvent (20 ml)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

20/03/2002

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

French Agency For Food, Environmental And Occupational Health & Safety

Authorisation number:

FR/V/6190958 0/2002

Date of authorisation status change:

20/03/2007

Reference member state:

Netherlands

Procedure number:

NL/V/0105/001

Concerned member states:

Austria Belgium France Germany Greece Ireland Italy Luxembourg Portugal
Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.